Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study

In this observational pilot study, we investigated the impact of Dolutegravir, Raltegravir, Elvitegravir (Integrase Strand Transfer Inhibitors, INSTIs), or boosted Darunavir (a Protease Inhibitor, PI) in combination with two nucleoside reverstranscriptase inhibitors (Emtricitabine/Tenofovir disoprox...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cristian Jianu, Corina Itu-Mureşan, Cristina Drugan, Irina Filipescu, Adriana Violeta Topan, Mihaela Elena Jianu, Ioana Iulia Morar, Sorana D. Bolboacă
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1917fccefd974944a0669bab8edc4dc9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1917fccefd974944a0669bab8edc4dc9
record_format	dspace
spelling	oai:doaj.org-article:1917fccefd974944a0669bab8edc4dc92021-11-25T06:13:57ZEvaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study1932-6203https://doaj.org/article/1917fccefd974944a0669bab8edc4dc92021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594820/?tool=EBIhttps://doaj.org/toc/1932-6203In this observational pilot study, we investigated the impact of Dolutegravir, Raltegravir, Elvitegravir (Integrase Strand Transfer Inhibitors, INSTIs), or boosted Darunavir (a Protease Inhibitor, PI) in combination with two nucleoside reverstranscriptase inhibitors (Emtricitabine/Tenofovir disoproxil or Lamivudine/Tenofovir disoproxil, NRTI) on four interleukins (IL-4, IL-10, IL-13, and IL-21) as immune activation markers in naïve HIV(Human Immunodeficiency Virus)-infected patients during the first six months of combined standard-of-care antiretroviral therapy (cART). Newly diagnosed with HIV-infected subjects and without any disease that could affect the immune activation markers were evaluated. The patients’ physicians recommended the cART as standard-of-care and the ILs were measured before cART and six months of cART. The levels of CD4+ T-cells count and CD4+/CD8+ ratio significantly increased at six months (P-value<0.02) regardless of the drugs, INSTIs or PI. However, a CD4+/CD8+ >1 was observed in 25% of patients treated with Raltegravir and half of those treated with Dolutegravir. At six months of cART, viral load was detectable in only 6/31 individuals. IL-21 had an undetectable level in 30/31 patients after six months of cART. Our results suggest the potency in restoring immune markers in HIV-infected patients with all investigated drugs. Dolutegravir showed a tendency to statistically significant changes in IL-4 and IL-10. A clinical trial with random allocation of medication and an extensive follow-up is needed to replicate this research and validate the usefulness of evaluated ILs as markers of cART effectiveness.Cristian JianuCorina Itu-MureşanCristina DruganIrina FilipescuAdriana Violeta TopanMihaela Elena JianuIoana Iulia MorarSorana D. BolboacăPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Cristian Jianu Corina Itu-Mureşan Cristina Drugan Irina Filipescu Adriana Violeta Topan Mihaela Elena Jianu Ioana Iulia Morar Sorana D. Bolboacă Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study
description	In this observational pilot study, we investigated the impact of Dolutegravir, Raltegravir, Elvitegravir (Integrase Strand Transfer Inhibitors, INSTIs), or boosted Darunavir (a Protease Inhibitor, PI) in combination with two nucleoside reverstranscriptase inhibitors (Emtricitabine/Tenofovir disoproxil or Lamivudine/Tenofovir disoproxil, NRTI) on four interleukins (IL-4, IL-10, IL-13, and IL-21) as immune activation markers in naïve HIV(Human Immunodeficiency Virus)-infected patients during the first six months of combined standard-of-care antiretroviral therapy (cART). Newly diagnosed with HIV-infected subjects and without any disease that could affect the immune activation markers were evaluated. The patients’ physicians recommended the cART as standard-of-care and the ILs were measured before cART and six months of cART. The levels of CD4+ T-cells count and CD4+/CD8+ ratio significantly increased at six months (P-value<0.02) regardless of the drugs, INSTIs or PI. However, a CD4+/CD8+ >1 was observed in 25% of patients treated with Raltegravir and half of those treated with Dolutegravir. At six months of cART, viral load was detectable in only 6/31 individuals. IL-21 had an undetectable level in 30/31 patients after six months of cART. Our results suggest the potency in restoring immune markers in HIV-infected patients with all investigated drugs. Dolutegravir showed a tendency to statistically significant changes in IL-4 and IL-10. A clinical trial with random allocation of medication and an extensive follow-up is needed to replicate this research and validate the usefulness of evaluated ILs as markers of cART effectiveness.
format	article
author	Cristian Jianu Corina Itu-Mureşan Cristina Drugan Irina Filipescu Adriana Violeta Topan Mihaela Elena Jianu Ioana Iulia Morar Sorana D. Bolboacă
author_facet	Cristian Jianu Corina Itu-Mureşan Cristina Drugan Irina Filipescu Adriana Violeta Topan Mihaela Elena Jianu Ioana Iulia Morar Sorana D. Bolboacă
author_sort	Cristian Jianu
title	Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study
title_short	Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study
title_full	Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study
title_fullStr	Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study
title_full_unstemmed	Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study
title_sort	evaluation of several serum interleukins as markers for treatment effectiveness in naïve hiv infected patients: a pilot study
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/1917fccefd974944a0669bab8edc4dc9
work_keys_str_mv	AT cristianjianu evaluationofseveralseruminterleukinsasmarkersfortreatmenteffectivenessinnaivehivinfectedpatientsapilotstudy AT corinaitumuresan evaluationofseveralseruminterleukinsasmarkersfortreatmenteffectivenessinnaivehivinfectedpatientsapilotstudy AT cristinadrugan evaluationofseveralseruminterleukinsasmarkersfortreatmenteffectivenessinnaivehivinfectedpatientsapilotstudy AT irinafilipescu evaluationofseveralseruminterleukinsasmarkersfortreatmenteffectivenessinnaivehivinfectedpatientsapilotstudy AT adrianavioletatopan evaluationofseveralseruminterleukinsasmarkersfortreatmenteffectivenessinnaivehivinfectedpatientsapilotstudy AT mihaelaelenajianu evaluationofseveralseruminterleukinsasmarkersfortreatmenteffectivenessinnaivehivinfectedpatientsapilotstudy AT ioanaiuliamorar evaluationofseveralseruminterleukinsasmarkersfortreatmenteffectivenessinnaivehivinfectedpatientsapilotstudy AT soranadbolboaca evaluationofseveralseruminterleukinsasmarkersfortreatmenteffectivenessinnaivehivinfectedpatientsapilotstudy
_version_	1718413968510287872

Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study

Ejemplares similares